價(jià)格 | ¥170 | ¥398 | ¥678 |
包裝 | 1mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2025-02-28 |
中文名稱:化合物 LY2886721 | 英文名稱:LY2886721 |
CAS:1262036-50-9 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.94% | 產(chǎn)品類別: 抑制劑 |
貨號(hào): T6058 |
名稱 | LY2886721 |
描述 | LY2886721, a BACE inhibitor, is used for the therapy of Alzheimer's Disease. |
激酶實(shí)驗(yàn) | The CTLs and NK cells (0.8×106/mL) are treated with the inhibitors L1 (10-20 μM) or Aloxistatin (20-30 μM) for 24 hr at 37°C in 24-well plates. Cells are then used in 51Cr-release assays or are lysed to examine perforin in Western blots. The inhibitor is also added at the same concentration during the 4 hr reactions in some 51Cr-release assays, as indicated. Cell lysates are prepared using NP-40 lysis buffer (25 mM HEPES, 250 mM NaCl, 2.5 mM ethylenediaminetetraacetic acid, 0.1% volume/volume Nonidet P-40) and total protein concentration is determined using the Bradford assay. Equal amounts of protein are loaded and resolved on 8% SDS-PAGE gels. Human or mouse perforin is detected using the appropriate antibodies as indicated. Anti-actin antibody is used as a loading control[2]. |
體外活性 | LY2886721 is an oral, small molecule of β-site amyloid protein cleaving enzyme (BACE) inhibitor with the potential to inhibit the synthesis of β-amyloid and thereby to slow the Clinicalal progression of AD. [1] LY2886721 can also targetγ-secretase to nhibit the synthesis of β-amyloid. [2] |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 1 mg/ml, Sonication is recommended. |
關(guān)鍵字 | BACE2 | Inhibitor | BACE | Beta-secretase | BBB | Alzheimer's | BACE1 | sAPPβ | LY 2886721 | LY2886721 | C99 | LY-2886721 | inhibit | disease | β-Secretase |
相關(guān)產(chǎn)品 | Loganin | Epiberberine | Aloeresin D | Phytic acid potassium | NB-360 | Atabecestat | Epiberberine chloride | Auraptene | Verubecestat | Eslicarbazepine Acetate | Tenuifolin | DSS30 |
相關(guān)庫 | 抑制劑庫 | 血腦屏障通透化合物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | ReFRAME 相關(guān)化合物庫 | 抗心血管疾病化合物庫 | 蛋白酶抑制劑庫 | 神經(jīng)退行性疾病化合物庫 | 口服活性化合物庫 | 藥物功能重定位化合物庫 |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥1600.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2025-03-24 | |
詢價(jià) |
VIP4年
|
湖北諾迪納生物技術(shù)有限公司
|
2025-03-07 | |
¥1047.90 |
VIP2年
|
上海阿拉丁生化科技股份有限公司
|
2025-02-27 | |
詢價(jià) |
南京百鑫德諾生物科技有限公司
|
2024-09-26 | ||
詢價(jià) |
Shanghai Yusheng Medchem Co., Ltd
|
2023-06-02 |